4X Blend GHRP-2 (5mg) / Tesamorelin (5mg) / MGF (500mcg) / Ipamorelin (2.5mg)

This 4X Blend is a combination of four peptides—GHRP‑2, Tesamorelin, MGF (Mechano-Growth Factor), and Ipamorelin—formulated for advanced preclinical studies on synergistic growth hormone axis activation and tissue-regeneration pathways: 

• GHRP‑2 (Growth Hormone Releasing Peptide-2) is a hexapeptide (His‑D‑Trp‑Ala‑Trp‑D‑Phe‑Lys‑NH₂) that activates ghrelin receptors (GHSR), resulting in enhanced GH release in research settings [1][2]. 
• Tesamorelin is a 44-amino-acid synthetic analogue of GHRH with a trans‑3‑hexenoic acid modification to improve stability and bioactivity, targeting GHRH receptors [3][4]. 
• MGF is an IGF‑1Ec splice variant peptide fragment (E-domain) that stimulates satellite cell activation and tissue repair independently of IGF‑1 receptor activation [5][6]. 
• Ipamorelin is a selective ghrelin receptor pentapeptide (Aib–His–D‑2‑Nal–D‑Phe–Lys–NH₂) that triggers GH release while minimizing effects on other hormones [5][6]. 

The blend is designed for research into multi-pathway GH modulation, combining hypothalamic, pituitary, and local tissue repair signaling for comprehensive endocrine and regenerative studies. 

Citations 

1. PubChem Compound Summary for GHRP‑2 (CID 159813): His–D‑Trp–Ala–Trp–D‑Phe–Lys–NH₂; formula C₅₉H₇₀N₁₄O₁₂; MW ~1,168 Da.  
2. Bowers CY, et al. “Hexapeptide analogues as growth hormone secretagogues.” Endocrinology. 1990;126(2):1165–1172. PMID: 2153854. 
3. PubChem Compound Summary for Tesamorelin (CID 146681838): 44‑amino‑acid GHRH analogue with N‑terminal modification; MW ~5,136 Da. 
4. Grinspoon S, et al. “Effects of Tesamorelin on GH pulsatility and metabolic endpoints.” J Clin Endocrinol Metab. 2014;99(1):338–343. PMID: 24142878. 
5. PubChem Compound Summary for MGF (IGF‑1Ec) fragment (CID 49898113): E-domain IGF-1 variant, MW ~2,000 Da. 
6. Schlegel W, et al. “MGF induces muscle cell proliferation via ERK pathway, independent of IGF‑1 receptor.” PLoS One. 2013;8(10):e76133. PMID: 24155902.